interactive schedule

Main scientific program

Saturday
May23

Other scientific sessions
Opening Session Saturday
17:00-18:30
Opening Session
Opening Reception Saturday
18:30-20:00
Opening Reception
-

In the industry-sponsored educational sessions, new clinical developments will be presented and new perspectives on particular topics of interest will be discussed.

Sunday
May24

09:00-10:30
Heart Disease: From Cradle to Coronary Care Unit
Chairpersons

Virgil Brown (Atlanta, USA) & Phil Barter (Sydney, Australia)

LDL Lowering Therapies
Evan Stein
Genetics: Use in Causality CVD
Sekar Kathiresan
CV Risk & Early Intervention
John Deanfield
Epidemiology of CVD
Kay Tee Khaw
11:00-12:45
Epidemiology of CVD and Current Risk Stratification
Chairpersons

Eran Leitersdorf (Jerusalem, Israel) & Naveed Sattar (Glasgow, UK)

Learning Objectives

The opinion on risk factors and how to treat them has developed during the last decades. This session will summarise main advances and current state-of-the art clinical approach. Specific emphasis will be given to emerging drug therapies.

From Framingham to EPIC-Norfolk: Risk factors in perspective (1948-2015)
Kay Tee Khaw
One pill for all or different strategies for different patients: Personalized epidemiology today
Frank Visseren
High-dose or low-dose statin, with ezetimibe or without ezetimibe: Where do we go from here in secondary prevention?
Colin Baigent
Pathogenesis of Atherosclerosis
Chairpersons

Yasufumi Sato (Sendai, Japan) & Rob de Winter (Amsterdam, The Netherlands)

Learning Objectives

The process behind inflammation and atherosclerosis will be discussed, including the role of the endothelium & angiogenesis and the pros and cons of animal models of atherosclerosis.

The inflammatory process as the driver behind the unstable patient and the ruptured plaque: What are the interventions?
Esther Lutgens
Atherogenesis and plaque vulnerability: Where endothelium and angiogenesis meet
Paul Quax
In which animal models of atherosclerosis can interventions be translated to human therapy?
Kylie Kavanagh
Novel Interventions in Blood Pressure Management
Chairpersons

Wiek van Gilst (Groningen, The Netherlands) & Thomas MacDonald (Dundee, UK)

Learning Objectives

To understand the role of sympathetic nervous system beyond blood pressure control; to address the most relevant aspects and novelties in the management of hypertension (difficult-to-treat hypertension, assessment of the role of 24-h ambulatory blood pressure monitoring, etc.).

Resistant Hypertension: Fact or Fiction?
Wilko Spiering
Ambulatory and central blood pressure measurement: What is their value in management of essential hypertension?
Bryan Williams
Variability in blood pressure readings: Impact on CV outcome and consequences for therapy
Peter Rothwell
Genetics of essential hypertension: Any new targets on the horizon?
Eric Sijbrands
Novel Oral Anticoagulants
Chairpersons

Ron Peters (Amsterdam, The Netherlands) & Philippe-Gabriel Steg (Paris, France)

Learning Objectives

Following this session, the attendee will have an understanding the latest findings on the use of novel oral anticoagulation in atrial fibrillation (AF), acute coronary syndrome (ACS), and Deep Venous Thrombosis (DVT).

The role of novel oral anticoagulants in the management of atrial fibrillation
Gregory Lip
What is the position of NOACs in acute coronary syndromes & secondary prevention?
Keith Fox
Deep Vein Thrombosis: Diagnostics and management in the latest state-of-the-art
Harry Büller
Chinese Satellite Symposium
11:00-12:30
Metabolic Cardiovascular Diseases: Translational Research on dyslipidemia, Obesity, diabetes and atherosclerosis;
Chairpersons

Depei Liu, George Liu

Scavenger receptors
Qi Chen
Roles of Energy restriction and Sirt 1 in atherogenesis
Depei Liu
Retinal proliferation and micro-vascular complications in diabetic mellitus
Jingkui Yang
Impact of alcohol consumption and ALDH2 mutations on atherogenesis
Aijun Sun
Human-like small animal models for atherogenesis
George Liu
Cell Matrix protease in the pathogenesis of experimental abdominal aortic aneurysm
Wei Kong
14:45-16:30
Diabetes and its Novel Interventions
Chairpersons

Max Nieuwdorp (Amsterdam, The Netherlands) & Jane Armitage (Oxford, UK)

Learning Objectives

The audience will gain understanding of the complexities of the relationship between diabetes and heart disease, the challenges and recommendations for optimal patient management, and the need for closer multi-professional collaboration between diabetes and cardiology specialists.

Novel antidiabetic drugs: The story of the trees and the forest; has their position crystallized?
Nikolaus Marx
Sugar versus fat: Is treatment of dyslipidemia relevant for diabetics?
Naveed Sattar
Sugar versus pressure: How important is blood pressure control in diabetics?
Thomas MacDonald
PCSK9: From Biology to Therapy
Chairpersons

Kees Hovingh (Amsterdam, The Netherlands) & Meral Kayıkçıoğlu (Izmir, Turkey)

Learning Objectives

To highlight the background and potential clinical impact of PCSK9 inhibition.

The biology of PCSK9 in humans: Just LDL-cholesterol or more?
Gilles Lambert
Genetic variation at the PCSK9 locus: A contributor to CV risk?
Helen Hobbs
The latest intervention in ACS: The monoclonal antibody against PCSK9
Philippe-Gabriel Steg
The PCSK9 protein: A key modulator of cardiovascular outcome
Nabil Seidah
Imaging & Atherosclerosis
Chairpersons

Jacqueline de Graaf (Nijmegen, The Netherlands) & Ahmed Tawakol (Boston, USA)

Learning Objectives

This session will discuss multiple imaging modalities that have been developed during the last 2 decades to characterize all aspects of atherosclerotic plaque and to identify vulnerable plaques.

Intracoronary grayscale IVUS leads the way: For how long?
Steven E. Nissen
Non-invasive imaging of the myocardium and the coronaries: Ready for prime time?
Zahi A. Fayad
Inflamed atherosclerosis: The clinical relevance of PET-CT
James H. F. Rudd
In-vivo imaging and the pathophysiology of human atherosclerosis
Erik SG Stroes
Inflammation, the Immune System & Atherosclerosis
Chairpersons

Peter Carmeliet (Leuven, Belgium) & Peter Libby (Boston, USA)

Learning Objectives

Update on recent findings linking the activity of immune cell classes to the atherosclerotic process.

Trained immunity and human atherogenesis; consequences for treatment?
Mihai G. Netea
Immunology, inflammation and cardiovascular disease
Jon Laman
The pro-inflammatory state as a risk factor for atherogenesis
Wolfgang Koenig
How to intervene in the pro-inflammatory state? Clinical studies in humans
Paul M. Ridker
Spanish Symposium
15:00-16:30
Clinical and genetic challenges in the Diagnosis and Management of FH
Chairpersons

Lina Badimón, Pedro Mata

What is new in FH treatment?
Raúl Santos
Role of the registries in the research and clinical practice: SAFEHEART follow-up Study
TBD
Efficiency model of a FH national detection and management program
Pablo Lázaro
Clinical and molecular characteristics of FH in Iberoamerica
Rodrigo Alonso
17:00-18:00
Controversies in Heart Disease and Nutrition: Are We What We Eat?
Chairpersons

John Kastelein (Amsterdam, The Netherlands) & Jaap Seidell (Amsterdam, The Netherlands)

Paleolithic Diet
Robb Wolf
Nutrition and CVD: Ten Steps Forward, Nine Steps Back
Martijn B. Katan
08:00-18:00

All day presenters from all over the world present their academic work in the I-Poster area. The poster area will be equipped with electronic poster boards, where poster presenters have the opportunity to present their work in a more dynamic fashion.

08:00-12:00 14:00-18:00

Our sponsors share novel insights from clinical development programs in our ISA Innovation Theatre and to engage participants in the future management of atherosclerosis and cardiovascular disease.

08:00-12:00 14:00-18:00

ISA2015 provides young scientists from all over the world with a stage for exchange and discussion. In a central location in the venue abstract presenters have the opportunity to discuss their science in an interactive and challenging format.

13:15-14:15 18:30-20:00

In the industry-sponsored educational sessions, new clinical developments will be presented and new perspectives on particular topics of interest will be discussed.

Monday
May25

08:30-10:30
Fat and Disease: Is it All About Triglycerides?
Chairpersons

Lale Tokgozoglu (Ankara, Turkey) & Christie Ballantyne (Houston, USA)

Obesity & CVD: it is not what you think it is!
Jean-Pierre Després
Triglyceridemia as Risk Factor for CVD
Rob Hegele
Central Role of ApoC3
Anne Tybjaerg-Hansen
Therapy of Hypertriglyceridemia
Michael Davidson
11:00-12:30
Obesity & Visceral Fat
Chairpersons

Esther Lutgens (Amsterdam, The Netherlands) & Jean-Pierre Després (Québec, Canada)

Learning Objectives

To discuss the role of adipose tissue and intestinal microbiota on the regulation of inflammation; to learn more about the importance of obesity for the development of coronary artery disease, and to discuss surgery as a treatment modality for obesity.

State of the art: Contribution of visceral fat and adiponectin to cardiovascular risk
Yuji Matsuzawa
Brown adipose tissue: A novel target to comBAT cardiovascular disease?
Patrick Rensen
The role of intestinal microbiota in the inflammation of visceral fat
Max Nieuwdorp
How effective is bariatric surgery at the short and long term?
Rachel Batterham
Single Gene Disorders of Lipoprotein Metabolism
Chairpersons

Eric Sijbrands (Rotterdam, The Netherlands) & Robert Hegele (London, Ontario, Canada)

Learning Objectives

Update on various lipoprotein anomalies, such as hypo- and hypertriglyceridemia, dysbetalipoproteinaemia, and interactions between TG and HDL metabolism.

Human syndromes associated with very low and very high triglyceride levels
Stephen G. Young
Dysbetalipoproteinaemia: A disease of remnants and high CV risk
David Marais
The high-TG, low-HDL syndrome: Very prevalent but not well understood
Jan Albert Kuivenhoven
Reverse Cholesterol Transport
Chairpersons

Attilio Rigotti (Santiago, Chile) & Jan Albert Kuivenhoven (Groningen, The Netherlands)

Learning Objectives

To discuss the mechanisms behind cholesterol efflux and immune function, removing cholesterol by reverse cholesterol transport, modulating the transport of lipids by Apo-A1 mimetic peptides, and the novel function of probucol in reverse cholesterol transport.

Cholesterol efflux, immune function and atherosclerosis
Alan Tall
How to get rid of cholesterol: Non-HDL mediated reverse cholesterol transport
Bert Groen
Apo-A1mimetic peptides; small molecules with large effects: Can they be the next ACS therapy?
Alan Remaley
Probucol: A novel function for an old molecule in reverse cholesterol transport
Shizuya Yamashita
New Insights Into Hypolipidaemic Drugs
Chairpersons

Andrey Susekov (Moscow, Russia) & Sam Tsimikas (La Jolla, USA)

Learning Objectives

Residual risk remains a significant challenge in management of CVD disease despite widespread use of statin monotherapy. This session will provide an update about the potential five year therapeutic opportunities to provide additional lipid management beyond current statin therapies.

Statins forever and nicotinic acid in the waste-bin? Data from clinical studies
Jane Armitage
MTP inhibition for hoFH and chilomicronemia?
Mariko Harada-Shiba
mRNA inhibition of ApoB synthesis: An alternative to LDL-receptor upregulation?
John JP Kastelein
The resurrection of ezetimibe: A story of perseverance
Harry R. Davis Jr.
Chinese Symposium Monday Morning
11:00-12:30
Metabolic Cardiovascular Diseases: Clinical Progress of prevention, diagnosis and therapeutics in CAD and stroke:
Chairpersons

Dong Zhao and Chunyu Zeng

Fully automated detection of corticospinal tract damage in chronic stroke patients
Gaojun Teng
Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease
Chunyu Zeng
Prognosis after mild to moderate ischemic stroke by stroke subtype: a multi-clinic registry study
Xunming Ji
14:45-16:30
Familial Hypercholesterolemia
Chairpersons

Raul Santos (Sao Paulo, Brazil) & Katherine Wilemon (South Pasadena, USA)

Learning Objectives

Overview on issues in diagnosis and treatment of familial hypercholesterolaemia.

Homozygous FH: From a lethal disorder to a manageable dyslipidemia
Derick Raal
Heterozygous FH: Amazingly prevalent and astonishingly diverse
Kees Hovingh
We need to diagnose heterozygous FH in childhood: The why and how
Samuel S. Gidding
Novel Insights into Lp(a)
Chairpersons

Bülent Behlül Altunkeser (Konya, Turkey) & Richard Češka (Prague, Czech Republic)

Learning Objectives

Update on the background and relevance of Lp(a), and treatment options for elevated Lp(a).

The epidemiology of Lp(a) in the general population and in those with CAD
Pia Kamstrup
New insights into Lipoprotein(a) biology and contributions to vascular disease
Marlys Koschinsky
How are we going to intervene in elevated Lp(a)? From PCSK9 to mRNA inhibition
Sotirios Tsimikas
Specific Lipoprotein(a) apheresis for coronary and carotid atherosclerosis regression in stable ischemic heart disease patients
Sergei Pokrovsky
HDL Functionality
Chairpersons

Miranda van Eck (Leiden, The Netherlands) & Ruth Frikke Schmidt (Copenhagen, Denmark)

Learning Objectives

Update on the discussion about HDL function based on new basic and clinical data.

The composition and atheroprotective function of the HDL particle: Latest insights
Kerry-Anne Rye
Why does the HDL particle give up during an acute coronary syndrome: The dysfunctional HDL syndrome
Ulf Landmesser
The endothelium as a target and a barrier for HDL (dys)function
Arnold von Eckardstein
Lipoprotein changes after HDL infusion: Do they translate into improved functionality?
Cesare Sirtori
Triglyceride-Rich Proteins
Chairpersons

Jacques Genest (Montreal, Canada) & Manuel Castro Cabezas (Rotterdam, The Netherlands)

Learning Objectives

To give an overview of the background of extreme hypertriglyceridemia, the role of triglyceride-rich lipoproteins as drivers of atherosclerosis, and therapeutic options to lower triglycerides.

Human syndromes characterized by extreme hypertriglyceridemia: From LPL to ApoC2 and back again
Daniel Gaudet
Are triglyceride-rich lipoproteins involved in atherogenesis? Genetics, epidemiology and biology tell the story
Rob Hegele
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
Christie M. Ballantyne
Russian Symposium I
15:00-16:30
Statin therapy at the crossroad of the decade: what we know and what we would like to know.
Chairpersons

Prof. Evgeny Shlyakhto, Dr. Andrey Susekov

Lowering LDL-С or non HDL-C with statins: Which comes first?
Andrey Susekov
Statins and instrumental validated end-points: are we ready to measure?
Andrey Obrezan
Statins in the treatment of patients after coronary revascularization: only secondary prevention?
Alexei Panov
Safety of statins: old songs about the main?
Zhanna D. Kobalava
17:00-18:00
The HDL Controversy: Is the Particle Irrelevant for Atherogenesis?
Chairpersons

Antonio Gotto (New York, USA) & Erik Stroes (Amsterdam, The Netherlands)

Biological Function of HDL
Ulf Landmesser
HDL Plays No Role in the Pathogenesis of Atherosclerosis
Børge Nordestgaard
08:00-18:00

All day presenters from all over the world present their academic work in the I-Poster area. The poster area will be equipped with electronic poster boards, where poster presenters have the opportunity to present their work in a more dynamic fashion.

08:00-12:00 14:00-18:00

Our sponsors share novel insights from clinical development programs in our ISA Innovation Theatre and to engage participants in the future management of atherosclerosis and cardiovascular disease.

08:00-12:00 14:00-18:00

ISA2015 provides young scientists from all over the world with a stage for exchange and discussion. In a central location in the venue abstract presenters have the opportunity to discuss their science in an interactive and challenging format.

15:00-16:30

06:30-08:00 13:15-14:15 18:30-20:00

In the industry-sponsored educational sessions, new clinical developments will be presented and new perspectives on particular topics of interest will be discussed.

Tuesday
May26

08:30-10:30
Inflammation, the Immune System and Heart Disease: Proof?
Chairpersons

Mihai Netea (Nijmegen, The Netherlands) & Paul Ridker (Boston, USA

Innate immunity in atherosclerosis: cause or companion?
Peter Libby
Adaptive immunity: The Janus of Atherosclerosis
Göran K. Hansson
Inflammation & Imaging
Ahmed Tawakol
Immunomodulation Therapy for Atherosclerosis
Jan Nilsson J
11:00-12:45
The Vulnerable Plaque
Chairpersons

Allard van der Wal (Amsterdam, The Netherlands) & Ira Tabas (New York, USA)

Learning Objectives

The session will focus on the complex mechanisms responsible for coronary instability. The audience will receive cutting-edge information on the complex link between coagulation and inflammation and on new potential therapeutic avenues.

The vulnerable atherosclerotic plaque; the evidence in mice compared to humans: Time for a resetting of targets?
Gerard Pasterkamp
The most recent insights into vulnerable plaque imaging in humans with CAD
Ton van der Steen
How to fight the fire: Therapies to reduce inflammation and rupture of vulnerable plaques
Stephen Nicholls
HDL Therapies
Chairpersons

Frank Visseren (Utrecht, The Netherlands) & Phil Barter (Sydney, Australia)

Learning Objectives

This session gives an overview of several treatment options to increase HDL-c.

HDL-like particle infusion to promote cholesterol efflux from macrophages and stimulate RCT in humans
Daniel Rader
Delipidation and reinfusion of native HDL: How a machine might be the future for ACS treatment
Bryan Brewer
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins
Wouter Jukema
The ApoC3 story: From basic science to metabolism to treatment
Frank Sacks
The Elderly Patient & CVD Prevention
Chairpersons

Eugeniy Shlyakhto (St. Petersburg, Russia) & Sophia de Rooij (Amsterdam/Groningen, The Netherlands)

Learning Objectives

The audience will identify the challenges faced by elderly patients with multiple comorbid conditions, and discuss strategies for supporting and managing patients with multimorbidity.

Family studies to unravel the missing heritability of CV risk – New approaches to genetic discovery
Peter Nilsson P
How are cardiovascular disease and dementia linked: A tale of two conditions
Ruth Frikke-Schmidt
Clinical significance of arterial stiffening in diabetics and the elderly: Consequences for diagnostics and therapy?
Coen Stehouwer
Cardiovascular Disease in Chronic Kidney Disease
Chairpersons

Dick de Zeeuw (Groningen, The Netherlands) & Naveed Sattar (Glasgow, UK)

Learning Objectives

Relevant aspects with respect to implications of renal disease on cardiovascular conditions are discussed.

The role of the angiopoietin/Tie2 complex in the atherogenesis of chronic kidney disease
Sascha David
The arterial glycocalyx, albuminuria and vascular damage in chronic kidney disease
Ton Rabelink
The role of dyslipidemia and its treatment in the prevention of nephron loss in CAD patients
David D. Waters
Russian Symposium II
11:00-12:30
Lipid studies in Russia: selected works
Chairpersons

Prof. Oxana Drapkina, Dr. Andrey Susekov

LDL apheresis in Russia: a 28 years experience
Gennadiy Konovalov
Statin therapy and liver: review of the current evidence
Oxana Drapkina
Familial hypercholesterolaemia in Russia: hopes and uncertainties
Marat Ezhov
Translation of basic research into anti-atherosclerotic therapy
Igor Sobenin
14:45-16:30
International Guidelines Update
Chairpersons

Željko Reiner (Zagreb, Croatia) & Tamio Teramoto (Tokyo, Japan)

Learning Objectives

In this session, different guidelines on the management of dyslipidemia are discussed and compared.

The ACC-AHA 2013 US prevention guidelines: America leads the way?
Neil J. Stone
The IAS guidelines: A more global view of intervention?
Philip Barter
The NLA guidance: A sharper view of the management of dyslipidemia?
Matthew Ito
A comparison of current guidelines: The good, the bad, and the uncertain
Kausik Ray
Innate and Adaptive Immunity in Atherosclerosis
Chairpersons

Theo van Berkel (Leiden, The Netherlands) & Paul Ridker (Boston, USA)

Learning Objectives

To get an overview of the contribution of immune cell classes to the atherosclerotic process.

The monocyte/macrophage as the key factor in the sequence between risk factor and unstable plaque
Matthias Nahrendorf
Defective inflammation resolution in atherosclerosis
Ira Tabas
The role of B- and T-lymphocytes in inflammation and atherosclerosis
Ziad Mallat
Apolipoproteins
Chairpersons

Jacqueline de Graaf (Nijmegen, The Netherlands) & Alan Remaley (Bethesda, USA)

Learning Objectives

This session provides insights in the biology of several apolipoproteins and their role in CV risk.

Genetics and biology of apolipoproteins and enzymes involved in the mechanism of ApoB containing lipoproteins
Daniel Rader
Mutations in ApoA1 and their influence on CV risk: A (mis)fit with the HDL hypothesis
Ernst J. Schaefer
Apo C3 as the new promotor of hypertriglyceridemia and CVD risk: From genetics to intervention
Sekar Kathiresan
LCAT mutations & CVD
Laura Calabresi
Evidence-Based Lifestyle Interventions
Chairpersons

John Deanfield (London, UK), Coen Stehouwer (Maastricht, The Netherlands)

Learning Objectives

To discuss the evidence and issues related to lifestyle measures for prevention.

How bad is smoking really: When and how did we acquire this evidence?
Richard Peto
Can physical exercise and exercise mimetics improve metabolic health in humans?
Patrick Schrauwen
The Mediterranean diet: The ideal strategy to lower CVD risk?
Emilio Ros
17:00-18:00
Statin Therapy versus Novel Interventions: The Age of Discontent
Chairpersons

J. Wouter Jukema (Leiden, The Netherlands) & John Deanfield (London, UK)

Statins Are Enough for the Prevention of CVD
Kausik Ray
Novel Interventions On Top of Statins Are Urgently Needed
Ulrich Laufs
08:00-18:00

All day presenters from all over the world present their academic work in the I-Poster area. The poster area will be equipped with electronic poster boards, where poster presenters have the opportunity to present their work in a more dynamic fashion.

08:00-12:00 14:00-18:00

Our sponsors share novel insights from clinical development programs in our ISA Innovation Theatre and to engage participants in the future management of atherosclerosis and cardiovascular disease.

08:00-12:00 14:00-18:00

ISA2015 provides young scientists from all over the world with a stage for exchange and discussion. In a central location in the venue abstract presenters have the opportunity to discuss their science in an interactive and challenging format.

11:00-12:30

06:30-08:00 13:15-14:15

In the industry-sponsored educational sessions, new clinical developments will be presented and new perspectives on particular topics of interest will be discussed.

Stay up to date, subscribe to the newsletter

Progression and prevention of atherosclerosis and a translation to relevance.